Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Catalent, Dow and Agere Pharmaceuticals.
We begin this week with an update from last. Having covered the appointment of Terry Robinson to Executive Director at Catalent’s Applied Drug Delivery Institute, we also have news that Dr. Ralph Lipp will join the team’s Advisory Board.
With over 20 years in industry and academia, Lipp – who is currently President and CEO of Lipp Life Sciencea – said he looked forward to leveraging his knowledge and experience to help “the Institute accomplish its important mission of delivering better treatments to patients.”
Read the latest regarding Catalent’s exploits into China here .
Oral bioavailability contract research and manufacturing organization Agere Pharmaceuticals has added new leadership roles in its Scientific and Business Areas:
- Ryan Minikis (left), formerly Sr. Director of Chemistry and Formulations, has been promoted to VP of Operations.
- Casey Jones (middle), an electronic design automation veteran, has joined Agere as VP of Corporate Development
- Dr. Sanjay Konagurthu joins as Senior Director of Formulation Science, coming from Bend Research
Marshall Crew, president and CEO of Agere, said: “As Agere enters our next phase of growth, we are bolstering and broadening our scientific, management and business expertise to ensure we continue to innovate and deliver the highest quality to our clients.”
Agere late last year added spray drying to its offering in response to demand for bioavailability boosting technology. See the article here .
Why not sign up to the “Bioavailability challenge 2013” a free to ‘attend’ online webinar series on March 20 focused on the difficulties developers face in ensuring their drug candidates are bioavailable.
Our editorial programme will feature contributions from Big Pharma firms Bristol-Myers Squibb (B-MS) and Hoffman La Roche and analysts group Frost & Sullivan will share its overview of the bioavailability services market.
The event will also feature presentations from scientists from Agere Pharmaceutical, Ashland, BASF, Bend, Dow, Capsugel, Catalent and Evonik.
Click here to sign up for the show. See you on March 20.
Dow has named Marc van Gerwen as Global Business Director for Dow Pharma & Food Solutions.
“Marc is the right person for the job,” said Neil Carr, Business President for Functional Materials. “After two years as Marketing and Commercial Director, he knows the business, and many of its customers. He has a demonstrated talent for working closely with them to get good results for all.”
Last month Dow completed its bioavailability trifecta by penning a deal with Cambrex which you can read about here .
Dr. Jon Gockerman has been appointed Senior Medical Director for Oncology at CRO Novella Clinical.
Gockerman has had 30 years of experience of oncology, hematology and clinical practice at Duke’s Department of Medicine.
Novella Clinical Chief Medical Officer Frank Santoro, MD, noted, “We are fortunate to bring Jon’s expertise and knowledge to Novella to further enhance our growing oncology division and medical oncology CRO services.”
Dr. Suzanne Gagnon has joined Idis as Chief Medical Officer responsible for leading global medical affairs and providing strategic medical and regulatory leadership across all business divisions.
For nearly ten years, Gagnon served as CMO and Executive Vice president at Icon Clinical Research and this new role will see her based at Idis' North American headquarters in Princeton, NJ.
Natalie Douglas, CEO of Idis said: "Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programs that balance stakeholder requirements and effectively address the needs of patients."
German Biopharma contract manufacturer Rentschler Biotechnologie has announced the appointment of Frank Ternes to its Executive Management Board.
Ternes previously served as Senior Vice President of Biopharmaceutical Contract Manufacturing at Boehringer Ingelheim.
"Mr. Ternes is an excellent addition to Rentschler's management board," said Dr. Nikolaus Rentschler, CEO and owner of the company. "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”